ubs upgrade to buy, page-10

TP - it's been going on for a while now - sad people. Such is life. As you say if anyone has an issue with a posting then bring it on - all criticism welcome if constructive.

Would be good to make TU and TD public.

Anyway, still good support at these elevated levels. Really don't see much in the 1/2 year report that will excite anyone.

Possible surprises for the upside; new delivery kit approved, individual doses being trialed, acceptance in Japan, new manufacturing facility planned for the west coast of the US, really good recruitment in the EU trial.

And for a 100 to 1 bet, going early to the FDA based on partial US results. Probably nearer to 10,000 to 1, but there are some precedents of presenting early data where the results are significant.

Possible downside - too many to list :-)